Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 3/20 | 0.36 |
| ▸ | TK1 | P04183 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL28141456 | 0.89 | XDH (0.36) | XDHALDH1A1GAAKMT2APNP | |
| SCHEMBL1445604 | 0.85 | ALDH1A1 (0.33) | XDHALDH1A1GAAKMT2A | |
| SCHEMBL5607948 | 0.84 | XDH (0.31) | XDHALDH1A1GAA | |
| SCHEMBL3291325 | 0.82 | CDK1 (0.47) | XDHALDH1A1GAAKMT2ATK1 | |
| SCHEMBL9001851 | 0.82 | XDH (0.37) | XDHALDH1A1GAAKMT2APNP | |
| SCHEMBL1901244 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL27562476 | 0.79 | XDH (0.42) | XDHALDH1A1KMT2APNPTK1 | |
| SCHEMBL22901881 | 0.78 | PI4KA (0.47) | XDHALDH1A1GAAKMT2APNP | |
| SCHEMBL16769795 | 0.78 | CDK2 (0.54) | ALDH1A1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL986800 | 0.78 | XDH (0.60) | XDHALDH1A1KMT2APNPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103796678-B | For HER2 bispecific antibody | 健玛保 | 2018-02-27 | — | — | CN | claimed |
| EP-2332565-A1 | Low dose methods for treating disorders in which TNFalpha activity is detrimental | Abbott Biotechnology Ltd. (BM) | 2011-06-15 | — | — | EP | claimed |
| EP-2295071-A1 | Low dose methods for treating disorders in which TNF-alpha activity is detrimental | Abbott Biotechnology Ltd (BM) | 2011-03-16 | — | — | EP | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-111565632-B | System and microtube conductivity for characterizing, diagnosing and treating a patient's health condition and methods of use thereof | 奥特美医疗有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-110475571-B | Replacement for cellular immunotherapy pre-conditioning for cytotoxicity | AVM生物技术有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-111032085-A | Combination of an immune checkpoint antagonist and a RANK-L (NF-KB ligand) antagonist or bispecific binding molecules thereof for use in cancer treatment or prevention and uses thereof | 昆士兰医学研究所理事会 | 2020-04-17 | — | — | CN | disclosed |
| EP-3615563-A1 | TUMOUR-TARGETING PEPTIDE VARIANTS | Cancer Research Technology Limited (GB) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197490-A1 | TUMOUR-TARGETING PEPTIDE VARIANTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-01 | — | — | WO | disclosed |
| CN-107810176-A | N menthyl benzimidazoles compounds as mIDH1 inhibitor | 拜耳制药股份公司 | 2018-03-16 | — | — | CN | disclosed |
| CN-103796678-B | For HER2 bispecific antibody | 健玛保 | 2018-02-27 | — | — | CN | disclosed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | disclosed |
| EP-1671121-A2 | SYSTEMS AND METHODS FOR DETECTING BIOLOGICAL FEATURES | Pathwork Informatics, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | disclosed |
| US-20060040903-A1 | Methods of use related to xerostomia | STOGNIEW MARTIN | 2006-02-23 | — | — | US | disclosed |
| WO-2005042760-A2 | SYSTEMS AND METHODS FOR DETECTING BIOLOGICAL FEATURES | PATHWORK INFORMATICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| CN-1494905-A | Medicine composition containing anti-tumor medicine and hydroximic acid derivative and having anti-tumor enhanced acitity and/or reducing side effect | N基因研究实验室公司 | 2004-05-12 | — | — | CN | disclosed |
| CN-1127984-C | Pharmaceutical composition containing antitumor drug and hydroximic acid derivative and having antitumor enhancing activity and/or reduced side effect | N GENE RES LAB INC (HU) | 2003-11-19 | — | — | CN | disclosed |
| CN-1263471-A | Pharmaceutical composition containing antitumor drug and hydroximic acid derivative and having antitumor enhancing activity and/or reduced side effect | N GENE RES LAB INC (US) | 2000-08-16 | — | — | CN | disclosed |